Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* A diagnosis of chronic rheumatologic conditions or inflammatory bowel disease or Duchenne muscular dystrophy requiring systemic glucocorticoids (i.v. or oral) within 12 months prior to screening~* Lumbar Spine BMDZ-score of -0.5 or worse~* Evidence of at least at least 1 vertebral compression fracture of Genant Grade 1 or higher (or radiographic signs of vertebral fracture) within 1 month from Screening visit OR One or more, low-trauma, lower extremity long-bone fracture which occurred sometime within the 2 years PRECEDING enrollment in the study OR Two or more, low-trauma, upper extremity long-bone fractures which occurred sometime within the 2 years PRECEDING enrollment in the study~* Consent/assent to study participation~Key Exclusion Criteria:~* History of primary bone disease (OI, Idiopathic Juvenile Osteoporosis, Rickets/Osteomalacia)~* Any medical condition that might have interfered with the evaluation of lumbar spine BMD, such as severe scoliosis or spinal fusion. Patients with less than 3 evaluable vertebrae by Dual Energy X-ray Absorptiometry (DXA) evaluation in the region of interest lumbar 1 (L1) to lumbar 4 (L4),~* Hypocalcemia and hypophosphatemia~* Serum 25-hydroxy vitamin D concentrations of \<20 ng/mL or \<50 nmol/L~* estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m2~* serum creatinine increase between Visit 1 and Visit 2 \>0.5 mg/dL (44.2 μmol/L)~* Uncontrolled symptoms of cardiac failure or arrhythmia~* Any prior use of bisphosphonates, or high dose sodium fluoride

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: EXPERIMENTAL): Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
- Placebo (Type: PLACEBO_COMPARATOR): Twice yearly i.v of infusion of Placebo (similar dosing as active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).